Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
作者信息
Hsu Yao-Chun, Chen Chi-Yi, Lin Jaw-Town
机构信息
Division of Gastroenterology and Hepatology, E-Da Hospital, Kaohsiung, Taiwan.
School of Medicine & Graduate Institute of Medicine, I-Shou University, Kaohsiung, Taiwan.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):e169-e172. doi: 10.3350/cmh.2024.1138. Epub 2024 Dec 23.
Abstract
摘要
相似文献
1
Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
Clin Mol Hepatol. 2025 Apr;31(2):e169-e172. doi: 10.3350/cmh.2024.1138. Epub 2024 Dec 23.
2
Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
Clin Mol Hepatol. 2025 Apr;31(2):603-605. doi: 10.3350/cmh.2024.0929. Epub 2024 Oct 29.
3
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
Clin Mol Hepatol. 2025 Apr;31(2):606-609. doi: 10.3350/cmh.2024.1078. Epub 2024 Dec 3.
4
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
Clin Mol Hepatol. 2025 Apr;31(2):e140-e142. doi: 10.3350/cmh.2024.0960. Epub 2024 Dec 3.
5
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.
Clin Mol Hepatol. 2025 Jan;31(1):213-226. doi: 10.3350/cmh.2024.0640. Epub 2024 Oct 17.
6
Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.
BMC Gastroenterol. 2022 Aug 17;22(1):387. doi: 10.1186/s12876-022-02471-y.
7
Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase.
J Clin Transl Hepatol. 2023 Oct 28;11(5):1011-1022. doi: 10.14218/JCTH.2023.00014. Epub 2023 Apr 10.
8
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):295-305. doi: 10.1016/S2468-1253(24)00431-X. Epub 2025 Feb 3.
9
Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
J Cell Biochem. 2019 Apr;120(4):6632-6641. doi: 10.1002/jcb.27959. Epub 2018 Oct 28.
10
Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.
Lancet Gastroenterol Hepatol. 2024 Apr;9(4):323-332. doi: 10.1016/S2468-1253(23)00449-1. Epub 2024 Feb 15.
本文引用的文献
1
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
Clin Mol Hepatol. 2025 Apr;31(2):e140-e142. doi: 10.3350/cmh.2024.0960. Epub 2024 Dec 3.
2
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
Clin Mol Hepatol. 2025 Apr;31(2):606-609. doi: 10.3350/cmh.2024.1078. Epub 2024 Dec 3.
3
Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
Clin Mol Hepatol. 2025 Apr;31(2):603-605. doi: 10.3350/cmh.2024.0929. Epub 2024 Oct 29.
4
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.
Clin Mol Hepatol. 2025 Jan;31(1):213-226. doi: 10.3350/cmh.2024.0640. Epub 2024 Oct 17.
5
Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection (Text Extract): Executive Summary.
Infect Dis Immun. 2024 Jul;4(3):103-105. doi: 10.1097/ID9.0000000000000128. Epub 2024 Jun 12.
6
Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.
Gut. 2025 Mar 6;74(4):628-638. doi: 10.1136/gutjnl-2024-332526.
7
Global burden of hepatitis B virus: current status, missed opportunities and a call for action.
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):524-537. doi: 10.1038/s41575-023-00760-9. Epub 2023 Apr 6.
8
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm.
Clin Mol Hepatol. 2023 Oct;29(4):869-890. doi: 10.3350/cmh.2022.0420. Epub 2023 Mar 14.
9
Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment.
J Clin Invest. 2022 Sep 15;132(18). doi: 10.1172/JCI161818.
10
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
J Hepatol. 2022 Jun;76(6):1249-1262. doi: 10.1016/j.jhep.2021.11.024.
Zotero 插件